Group 1 - The core viewpoint of the article highlights the fluctuation of the Guozheng Free Cash Flow Index, which experienced a decline of approximately 0.4% in early trading on January 7, with component stocks showing mixed performance [1] - Notable stocks such as Jiashitang, China Chemical, Anfu Technology, Mona Lisa, and Nanshan Aluminum saw gains, indicating selective strength within the market [1] - The largest free cash flow ETF (159201) has seen a continuous net inflow of funds totaling 641 million yuan over the past four days, reaching a new high of 9.213 billion yuan since its inception [1] Group 2 - Dongwu Securities' research report suggests that the A-share market is experiencing an improvement in liquidity, driven by cross-border capital inflows and the upcoming insurance "New Year" funds entering the market [1] - The report indicates that the recovery of the RMB exchange rate may boost market sentiment and potentially lead to incremental capital through corporate and household sectors [1] - Free cash flow is emphasized as the foundation for dividend distribution, focusing on a company's internal growth capabilities, while dividend strategies emphasize the results of dividend distribution [1] Group 3 - The free cash flow strategy is noted to complement growth stock investments, serving as a foundational tool for balancing such investments [1] - The free cash flow ETF (159201) and its linked funds (A: 023917; C: 023918) closely track the Guozheng Free Cash Flow Index, with management fees at 0.15% and custody fees at 0.05%, representing the lowest rates in the market [1]

| 日期 | 当日涨跌幅（%） | 换手率（%） | 主力资金净流入（万元） | | --- | --- | --- | --- | | 2026.01.06 | 10.00 | 4.10 | 10140.83 | | 2026.01.05 | 10.03 | 7.71 | 9438.20 | | 2025.12.31 | -2.05 | 1.84 | -1444.06 | | 2025.12.30 | -0.14 | 1.36 | -5.53 | | 2025.12.29 | -2.85 | 2.61 | -1358.05 | | 2025.12.26 | -0.26 | 2.28 | -218.48 | | 2025.12.25 | -0.53 | 2.03 | -681.93 | | 2025.12.24 | 0.33 | 2.32 | -887.15 | | 2025.12.23 | -2.38 | 3.62 | -730.01 | | 2025.12.22 | -2.51 | 3.63 | -917.58 | （文章来源：证券时报网） 近日该股表现 嘉事堂盘中涨停，已连收3个涨停板，截至9:25，该 ...

Market Performance - The pharmaceutical commercial sector increased by 0.97% compared to the previous trading day, with Luyuan Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 4083.67, up by 1.5%, while the Shenzhen Component Index closed at 14022.55, up by 1.4% [1] Individual Stock Performance - Key stocks in the pharmaceutical commercial sector showed significant gains, with Yinghe Pharmaceutical rising by 10.02% to a closing price of 22.72, and Jiashitang also increasing by 10.00% to 17.38 [1] - Other notable performers included Saili Medical and Renmin Tongtai, both showing increases of 10.00% and 2.64% respectively [1] Trading Volume and Value - Yinghe Pharmaceutical had a trading volume of 636,200 shares, resulting in a transaction value of approximately 1.396 billion yuan [1] - Jiashitang and Saili Medical also reported substantial trading volumes of 119,600 and 74,200 shares, with transaction values of around 208 million yuan and 185 million yuan respectively [1] Capital Flow Analysis - The pharmaceutical commercial sector experienced a net outflow of 188 million yuan from institutional investors and 252 million yuan from speculative funds, while retail investors saw a net inflow of 439 million yuan [2] - The capital flow data indicates varying investor sentiment, with retail investors showing a positive trend in the sector [2] Stock-Specific Capital Flow - Luyuan Pharmaceutical had a net inflow from retail investors of approximately 1.02 billion yuan, despite a net outflow from institutional and speculative investors [3] - Jiashitang and Saili Medical also experienced mixed capital flows, with Jiashitang seeing a net inflow of 84.96 million yuan from institutional investors [3]

Market Performance - The pharmaceutical commercial sector increased by 1.77% compared to the previous trading day, with Jia Shitang leading the gains [1] - The Shanghai Composite Index closed at 4023.42, up 1.38%, while the Shenzhen Component Index closed at 13828.63, up 2.24% [1] Individual Stock Performance - Jia Shitang (002462) closed at 15.80, up 10.03% with a trading volume of 224,800 shares [1] - Saily Medical (603716) closed at 22.61, up 10.02% with a trading volume of 133,500 shares [1] - Baiyang Pharmaceutical (301015) closed at 25.23, up 6.91% with a trading volume of 83,200 shares [1] - Other notable performers include Dajia Weikang (301126) up 6.51%, and Run Da Medical (603108) up 5.82% [1] Capital Flow Analysis - The pharmaceutical commercial sector saw a net inflow of 231 million yuan from institutional investors, while retail investors contributed a net inflow of 71.88 million yuan [2] - However, there was a net outflow of 303 million yuan from speculative funds [2] Detailed Capital Flow for Key Stocks - Saily Medical (603716) had a net inflow of 1.59 billion yuan from institutional investors, but a net outflow of 71.84 million yuan from speculative funds [3] - Jia Shitang (002462) experienced a net inflow of 86.98 million yuan from institutional investors, with a net outflow of 45.96 million yuan from speculative funds [3] - Hua Ren Health (301408) had a net inflow of 45.75 million yuan from institutional investors, but a significant net outflow of 65.32 million yuan from retail investors [3]

Market Overview - The Shanghai Composite Index closed at 4023.42 points, above the six-month moving average, with an increase of 1.38% [1] - The total trading volume of A-shares reached 30,483.30 billion yuan [1] Stocks Above Six-Month Moving Average - A total of 313 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - BeiYikang (证券代: 920199) with a deviation rate of 19.09% and a price increase of 29.98% [1] - *ST Huike (证券代: 300561) with a deviation rate of 18.68% and a price increase of 19.99% [1] - Weisi Medical (证券代: 688580) with a deviation rate of 18.24% and a price increase of 20.00% [1] Stocks with Smaller Deviation Rates - Stocks with smaller deviation rates that have just crossed the six-month moving average include: - Garden Holdings (证券代: 300430) with a deviation rate of 13.12% and a price increase of 19.98% [1] - Hongya CNC (证券代: 301033) with a deviation rate of 13.22% and a price increase of 20.00% [1] - Zhongke Sanhuan (证券代: 688314) with a deviation rate of 12.97% and a price increase of 19.99% [1]

12月31日，嘉事堂盘中下跌2.05%，截至13:20，报14.36元/股，成交5557.14万元，换手率1.32%，总市 值41.89亿元。 嘉事堂今年以来股价涨12.63%，近5个交易日跌5.71%，近20日跌7.24%，近60日涨4.28%。 分红方面，嘉事堂A股上市后累计派现8.74亿元。近三年，累计派现2.16亿元。 今年以来嘉事堂已经1次登上龙虎榜，最近一次登上龙虎榜为5月8日，当日龙虎榜净买入-5345.21万 元；买入总计3524.90万元 ，占总成交额比6.51%；卖出总计8870.11万元 ，占总成交额比16.37%。 责任编辑：小浪快报 资料显示，嘉事堂药业股份有限公司位于北京市海淀区昆明湖南路11号1号楼，成立日期1997年4月22 日，上市日期2010年8月18日，公司主营业务涉及以医药批发、零售为主营业务模式的医药商业经营。 主营业务收入构成为：商业收入100.00%。 嘉事堂所属申万行业为：医药生物-医药商业-医药流通。所属概念板块包括：医药电商、证金汇金、医 疗器械、小盘、冷链物流等。 资金流向方面，主力资金净流出902.34万元，特大单买入0.00元，占比0.00%，卖出42 ...

Core Viewpoint - The company emphasizes its commitment to its responsibilities as a central enterprise, focusing on core business development and enhancement [1] Group 1: Business Strategy - The company is strengthening its core business in pharmaceuticals, medical devices, and health products sales and distribution [1] - It aims to improve service capabilities and consolidate its market position [1] - The company plans to expand its business coverage and enhance cooperation with manufacturers [1] Group 2: Development Goals - The company is implementing multiple measures to promote sustainable and stable development [1]

Group 1 - The core point of the article is that as of December 19, 2025, the company will have over 24,000 shareholders [2]

证券日报网讯12月25日，嘉事堂（002462）在互动平台回答投资者提问时表示，公司今年已取得由中质 协质量保证中心颁发的《合规管理体系认证证书》(证书编号：00625CMS20005ROM)。本次获得合规 管理体系认证证书，标志着公司合规管理水平已接轨国际标准，积极践行合规创造价值的理念，还将持 续深耕合规管理体系建设，为经营活动开展提供合规的管理保障。 ...

Group 1 - The core viewpoint of the news is that 嘉事堂's stock has experienced fluctuations, with a current price of 15.23 yuan per share and a market capitalization of 4.443 billion yuan, reflecting a year-to-date increase of 19.45% [1] - As of November 20, 嘉事堂 had 22,000 shareholders, a decrease of 3.28% from the previous period, with an average of 13,248 circulating shares per shareholder, which is an increase of 3.39% [2] - 嘉事堂's main business revenue is entirely derived from commercial income, indicating a focused business model in pharmaceutical wholesale and retail [1] Group 2 - For the period from January to September 2025, 嘉事堂 reported a revenue of 14.459 billion yuan, a year-on-year decrease of 21.80%, and a net profit attributable to shareholders of 141 million yuan, down 38.81% year-on-year [2] - 嘉事堂 has distributed a total of 874 million yuan in dividends since its A-share listing, with 216 million yuan distributed over the past three years [3]